CLINICAL_TRIALS
trial_result
· 2025-09-19
Clinical Trial Update: Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease [Phase 2]
Summary
Phase 2 dose-response study evaluating Cellavita HD in Huntington disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Azidus Brasil | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-09-19